US Cosmetics FDA Compliance is the primary barrier all private label skincare teams must overcome to sell products across North America.
I’ve supported numerous overseas clients exporting skincare to the US, and most pitfalls arise from misinformation regarding FDA rules. Plenty of brands think the FDA will issue official approval certifications for cosmetics. Only shortly before shipping do they notice unregistered factories or non-compliant labels, resulting in full shipments detained by customs.
Without overly complex jargon, this article breaks down registration and labeling regulations, allowing you to handle compliance matters well ahead of product development.
1.The US Market: Promising yet Full of Hidden Pitfalls
The U.S. market offers favorable access yet carries plenty of hidden risks.
The United States does not mandate pre-market official approvals for cosmetics, resulting in relatively low entry barriers that even small brands can break into the market easily — this is its biggest advantage. Nonetheless, vague regulatory boundaries make it easy to stumble over US Cosmetics FDA Compliance. Following the implementation of MoCRA, facility registration, product listing, and adverse event reporting have all become mandatory obligations. Missing even a single required element on product labels can lead to shipments being detained by customs. Many teams delay compliance work until shortly before shipment, which poses extreme risks. Any revisions to formulas or relabeling will completely disrupt the planned product launch timeline.
Three Most Common Compliance Misconceptions
- Believing “no pre-market approval equals unrestricted sales”: Companies overlook facility registration and mandatory label requirements, assuming cosmetics can be sold freely without official FDA authorization.
- Affixing functional claims such as acne removal and skin whitening directly on labels will cross the OTC drug regulatory line.
- Seeking compliance checks only after samples are finalized: Major formula revisions become necessary post-development, doubling both time costs and financial expenditure.
Three Preemptive Compliance Steps
- Confirm product classification (cosmetic vs. drug) prior to product development.
- Conduct ingredient compliance screening during the formula development phase.
- Follow the official FDA label checklist before designing packaging artwork.
2.Draw the Line First: Cosmetic or Drug
This is the prerequisite for all subsequent compliance work. Conventional cosmetics are intended for cleansing, beautification and appearance enhancement, including creams, shampoos and perfumes. Appearance-focused claims such as “anti-aging appearance” are generally acceptable. However, once your labels or advertisements state claims like acne treatment, skin whitening, spot fading or sun protection, the product will likely be categorized as an OTC drug. It will then need to comply with the monograph system or new drug application procedures, and its label must adopt the Drug Facts format.
Sunscreen represents a typical compliance pitfall. Standalone sunscreens are regulated as OTC drugs, and daily moisturizers labeled with SPF values also require extra caution.
| Dimensions | Conventional cosmetics | OTC drugs (such as sunscreens and acne treatment products) |
| Regulatory Jurisdiction | FD&C Act + FPLA | OTC Drug Monograph |
| pre-market | no pre-market approval required | must follow the drug regulatory pathway |
| label | INCI ingredients listed in descending order of predominance | Drug Facts Label Format |
| MoCRA Registration | be required | Exempt from cosmetic facility registration via compliance with drug establishment registration |
This dividing line directly determines your registration pathway and forms the underlying logic behind US Cosmetics FDA Compliance. Aligning with regulatory consultants in the early stages of product development saves the most time and avoids unnecessary trouble.
A simple rule to judge this classification boundary is to check your marketing claims: whether they intend to affect the body’s structure or physiological functions
Claim Zones: Green & Red
Green Zone (Generally Safe Cosmetic Claims)
These only describe surface appearance and sensory effects, will not trigger drug regulation: moisturize, cleanse, add shine, improve the appearance of fine lines
Red Zone (High-Risk Drug Trigger Claims)
These imply altering bodily structure or physiological functions, forcing the product onto the OTC drug pathway: treat acne, cure eczema, prevent aging, reduce wrinkles
3.MoCRA Two-Step Registration
MoCRA was enacted at the end of 2022, and the FDA officially enforced mandatory facility registration and product listing starting July 1, 2024. When pursuing full U.S. cosmetic FDA compliance, registration is merely the first half of compliance work; the ingredient information submitted in product listings must match the ingredient details printed on product labels perfectly.
A critical reminder: MoCRA registration does not constitute FDA endorsement or approval of your cosmetic products. Obtaining an FEI number does not mean your goods have been officially approved by the FDA.
Step 1: Cosmetic Facility Registration
All facilities engaged in cosmetic manufacturing or processing are required to register with the FDA. Applicants first obtain an FEI (Establishment Identifier) number, complete formal registration, and renew the registration every two years. The first biennial renewal window will fall around July 2026.
Overseas manufacturing facilities are obligated to appoint a designated U.S. Agent, who acts as the official liaison to communicate with the FDA, respond to official inquiries, and coordinate FDA facility inspections.
The small-business exemption applies only to a narrow scope of enterprises. Facilities producing eye-area cosmetics, injectable beauty products, ingested oral cosmetics, or long-wear formulas lasting over 24 hours are ineligible for this exemption.
Step 2: Product Listing
The Responsible Person (the manufacturer, packager or distributor named on product labels) must submit an individual product listing to the FDA for every cosmetic item launched on the U.S. market, accompanied by the complete ingredient inventory, with annual updates required.
The facility FEI number stated in each product listing must correspond exactly to the one obtained in Step 1. Therefore, the fixed sequence is: complete facility registration first, then proceed with product listing.
The FDA has launched the Cosmetics Direct online electronic submission portal, and online filing is strongly recommended for efficiency and accuracy.
MoCRA Compliance Timeline
- December 2022: MoCRA was formally enacted
- December 2023: FDA issued the final official implementation guidance
- July 2024: Mandatory enforcement of facility registration and product listing took effect
- July 2026: The first biennial registration renewal window opens
4.Label Compliance Checklist
US Cosmetics FDA Compliance Labeling Requirements for American Cosmetics Can Be Condensed Into a Single Checklist, governed primarily by the U.S. Fair Packaging and Labeling Act (FPLA) and 21 CFR Part 701. All labeling text must be presented in English. The principal display panel shall display the product identity statement and net contents declaration; the information panel (located to the right of the principal display panel) shall list ingredients, responsible entity information, and precautionary warning statements.
| Mandatory Label Elements | Mandatory Requirements |
| Product Identity Statement | State the common name of the product on the principal display panel, e.g., “Facial Moisturizer” |
| Net Contents | Both US customary and metric units shall be used, e.g., “1.7 fl oz / 50 mL”, placed at the bottom of the principal display panel. |
| Ingredient List | List ingredients by INCI names in descending order of concentration; font size no less than 1/16 inch (1/32 inch permitted for small packages). |
| Name and address of the responsible party | Physical address located in the United States (can be supplied by a compliance agent) |
| Country of Origin | Imported products must indicate the country of origin in English, such as “Made in China”, “Made in Korea”, “Made in France”, etc. |
| Warning Statements | Examples: “External use only”, “Avoid contact with eyes” |
Country of Origin Marking: Country of origin is mandatory
Under the Tariff Act of 1930, goods imported into the United States must bear an English country-of-origin marking. Regardless of the manufacturing location, listing only the factory address is insufficient; the corresponding English origin label is required, such as “Made in China”, “Made in Korea”, “Made in France”, and so on. If the brand owner is not the manufacturer, phrases including “Manufactured for…” or “Distributed by…” shall be added to clarify the relationship, to prevent being deemed mislabeled. Where other languages appear on the label, all mandatory information must be accompanied by English counterparts.
Ingredient Nomenclature: INCI names are compulsory
Ingredients must adopt International Nomenclature Cosmetic Ingredient titles. For instance, “Sodium Hyaluronate” shall be used instead of the Chinese term for hyaluronic acid, and only FDA-certified lake names are allowed for colorants. Ingredients are listed in descending order by concentration; components accounting for less than 1% may be arranged in any order. Fragrances can be simply marked as “fragrance / parfum”.
Common Net Content Mistakes
- Using metric units alone or Chinese characters only — the US mandates US customary units as the primary measurement on the principal display panel, with metric units permitted alongside.
- Undersized fonts — text on the principal display panel shorter than 1/16 inch will result in non-compliance.
5.Ingredient red lines
Integrate US Cosmetics FDA Compliance into the formulation stage to avoid extensive revisions prior to launch. The following points are most commonly overlooked:
Four categories of prohibited and restricted ingredients
- Prohibited substances: mercury compounds (commonly found in illegal whitening goods), certain CFC propellants, unapproved colorants, and formaldehyde contained in spray products, etc.
- Restriction thresholds: Salicylic acid exceeding 2% concentration is regulated as an OTC drug; hydroquinone and retinoic acid are pharmaceutical ingredients and cannot be incorporated into ordinary cosmetics.
- Colorant approval: Only varieties listed and certified under FDA 21 CFR Part 74 are permitted; batch certification is required for some options, with stricter standards specifically for eye cosmetics.
- Claiming red lines: Phrases such as “treat acne / whiten / reduce wrinkles” will be regarded as drug claims; use wording centered on “appearance” instead, for instance “brighten dull skin”.
Real common case example: An acne care product was entirely confiscated and destroyed by the FDA for bearing the phrase “Acne Treatment” on packaging, which was deemed an unapproved pharmaceutical product. Revising the wording to “helps reduce the appearance of blemishes” keeps the product classified as a cosmetic. Minor differences in phrasing determine whether your product falls under cosmetic or pharmaceutical regulatory pathways.
Pre-compliance recommendations
- Conduct an ingredient compliance screening before finalizing the formula.
- Retain records of microbial testing, preservative challenge testing and stability testing.
- Track the proposed regulations on fragrance allergens and prepare ingredient files in advance.
6.Post-Marketing Obligations
Compliance obligations do not end upon shipment. Severe adverse events must be reported to the FDA via the CAERS system within 15 business days, with all relevant documents retained for 6 years for official review. Complete product safety substantiation files are also mandatory, generally covering formulas, ingredient safety data, test results and historical usage records.
Record Retention Checklist
- Serious adverse events: Submit reports to the CAERS system within 15 business days
- Record preservation: All associated documents stored for 6 years for inspection
- Safety substantiation: Maintain full documentation including formulas, lab test data and product usage history
- GMP transition: The final FDA cosmetic GMP rule has not yet been issued; compliance practices are recommended based on ISO 22716 and official industry guidelines
7.Treat regulatory compliance as your starting line.
US Cosmetics FDA compliance is not a one-time task, but an ongoing process spanning formulation, labeling and post-launch management. Advancing facility registration and label review to the product development phase can prevent last-minute revisions prior to shipment and customs detention.
If you are planning to launch your private label into the US market, feel free to contact us. We offer compliance support covering product formulation consultation, label verification and manufacturing facility registration, helping your products enter the US marketplace smoothly.
For official references, please check FDA guidelines regarding cosmetic facility registration and product listing, as well as the comprehensive summary of cosmetic labeling requirements.
